# The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps

> **NCT05873803** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Chronic Rhinosinusitis with Nasal Polyps

## Interventions

- **BIOLOGICAL:** GR1802 injection
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT05873803
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-08
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05873803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05873803, "The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05873803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*